

J Louise Jones

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9038854/publications.pdf>

Version: 2024-02-01

33
papers

2,388
citations

304743

22
h-index

434195

31
g-index

33
all docs

33
docs citations

33
times ranked

3904
citing authors

#	ARTICLE	IF	CITATIONS
1	Characterization of the Immune Microenvironment in Inflammatory Breast Cancer Using Multiplex Immunofluorescence. <i>Pathobiology</i> , 2023, 90, 31-43.	3.8	4
2	Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma <i>in situ</i> : Results from the UK/ANZ DCIS Trial. <i>Clinical Cancer Research</i> , 2021, 27, 2861-2867.	7.0	9
3	Prognostic and Predictive Value of HER2 Expression in Ductal Carcinoma <i>In Situ</i> : Results from the UK/ANZ DCIS Randomized Trial. <i>Clinical Cancer Research</i> , 2021, 27, 5317-5324.	7.0	17
4	Development of a Validated Exam to Assess Pathologist Knowledge of Genomic Oncology. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 453-456.	2.5	0
5	Subcellular mRNA Localization Regulates Ribosome Biogenesis in Migrating Cells. <i>Developmental Cell</i> , 2020, 55, 298-313.e10.	7.0	50
6	Cancer Burden Is Controlled by Mural Cell- β 3-Integrin Regulated Crosstalk with Tumor Cells. <i>Cell</i> , 2020, 181, 1346-1363.e21.	28.9	53
7	Derivation of a nuclear heterogeneity image index to grade DCIS. <i>Computational and Structural Biotechnology Journal</i> , 2020, 18, 4063-4070.	4.1	8
8	Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL): an overview of presentation and pathogenesis and guidelines for pathological diagnosis and management. <i>Histopathology</i> , 2019, 75, 787-796.	2.9	45
9	PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer. <i>Cell Reports</i> , 2018, 22, 2469-2481.	6.4	34
10	Time for change: a new training programme for morpho-molecular pathologists?. <i>Journal of Clinical Pathology</i> , 2018, 71, 285-290.	2.0	21
11	A 3D <i>in vitro</i> model of the human breast duct: a method to unravel myoepithelial-luminal interactions in the progression of breast cancer. <i>Breast Cancer Research</i> , 2017, 19, 50.	5.0	31
12	Loss of MMP-8 in ductal carcinoma <i>in situ</i> (DCIS)-associated myoepithelial cells contributes to tumour promotion through altered adhesive and proteolytic function. <i>Breast Cancer Research</i> , 2017, 19, 33.	5.0	29
13	Morphomolecular pathology: setting the framework for a new generation of pathologists. <i>British Journal of Cancer</i> , 2017, 117, 1581-1582.	6.4	16
14	The Initiator Methionine tRNA Drives Secretion of Type II Collagen from Stromal Fibroblasts to Promote Tumor Growth and Angiogenesis. <i>Current Biology</i> , 2016, 26, 755-765.	3.9	57
15	Stromal characteristics may hold the key to mammographic density: the evidence to date. <i>Oncotarget</i> , 2016, 7, 31550-31562.	1.8	20
16	The clinical and functional significance of c-Met in breast cancer: a review. <i>Breast Cancer Research</i> , 2015, 17, 52.	5.0	146
17	β 6 Expression in Myoepithelial Cells: A Novel Marker for Predicting DCIS Progression with Therapeutic Potential. <i>Cancer Research</i> , 2014, 74, 5942-5947.	0.9	32
18	Therapeutic Targeting of Integrin β 6 in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	132

#	ARTICLE	IF	CITATIONS
19	Altered Microenvironment Promotes Progression of Preinvasive Breast Cancer: Myoepithelial Expression of $\alpha 6$ Integrin in DCIS Identifies High-risk Patients and Predicts Recurrence. <i>Clinical Cancer Research</i> , 2014, 20, 344-357.	7.0	77
20	Rigidity sensing and adaptation through regulation of integrin types. <i>Nature Materials</i> , 2014, 13, 631-637.	27.5	304
21	Hard X-ray dark-field imaging with incoherent sample illumination. <i>Applied Physics Letters</i> , 2014, 104, .	3.3	145
22	GATA3 Mutations Found in Breast Cancers May Be Associated with Aberrant Nuclear Localization, Reduced Transactivation and Cell Invasiveness. <i>Hormones and Cancer</i> , 2013, 4, 123-139.	4.9	28
23	Jekyll and Hyde: the role of the microenvironment on the progression of cancer. <i>Journal of Pathology</i> , 2011, 223, 163-177.	4.5	309
24	Clinical and functional significance of $\alpha 11$ integrin expression in breast cancer: a novel cell surface marker of the basal phenotype that promotes tumour cell invasion. <i>Journal of Pathology</i> , 2011, 223, 646-658.	4.5	33
25	Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. <i>Breast Cancer Research</i> , 2009, 11, R24.	5.0	101
26	Matrix Metalloproteinase-8 Functions as a Metastasis Suppressor through Modulation of Tumor Cell Adhesion and Invasion. <i>Cancer Research</i> , 2008, 68, 2755-2763.	0.9	172
27	Overdiagnosis and overtreatment of breast cancer: Progression of ductal carcinoma in situ: the pathological perspective. <i>Breast Cancer Research</i> , 2006, 8, 204.	5.0	55
28	Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. , 1999, 189, 161-168.		166
29	Molecular pathology of breast cancer and its application to clinical management. <i>Cancer and Metastasis Reviews</i> , 1997, 16, 5-27.	5.9	53
30	Alteration of stromal protein and integrin expression in breast—a marker of premalignant change?. <i>Journal of Pathology</i> , 1992, 167, 399-406.	4.5	184
31	In vitro modulation of cellular localization of milk fat globule membrane antigens in human breast carcinomas. <i>Journal of Pathology</i> , 1991, 164, 127-133.	4.5	2
32	An immunohistochemical and in situ hybridization study of c-myc and c-erbB-2 expression in primary human breast carcinomas. <i>Journal of Pathology</i> , 1989, 158, 97-105.	4.5	51
33	The assessment of in vitro modulation of milk fat globule membrane expression by human breast carcinomas. <i>Journal of Pathology</i> , 1987, 153, 51-60.	4.5	4